Spread the love

A recent study from the Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA shows that “DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier.” This study was published in the 27 July  2014 issue of Nature  by Prof André NussenzweigMargarida A. Santos, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Differentiation therapy for Human Leukaemia: Resistin functions as an anti-cancer barrier by promoting differentiation of leukaemic cells via up regulation of Histone methyl-transferase MLL4. By increasing the expression of Resistin in myeloid leukaemic cells, one may promote differentiation of leukaemic cells. Together, this study suggests that pharmacological formulations encompassinResistin or its activators” may be used to treat human leukaemia.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan,  Differentiation therapy for Human Leukaemia: Resistin functions as an anti-cancer barrier by promoting differentiation of leukaemic cells via up regulation of Histone methyl-transferase MLL4, 7/October/2014,  12.31 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org


Spread the love